Bevacizumab 1.75 mg/0.07 mL - 0.25 mL syringe, Intravitreal, 0.07 mL Total Volume, Rx Only, Hospi...
FDA Recall #D-0003-2026 — Class II — September 22, 2025
Product Description
Bevacizumab 1.75 mg/0.07 mL - 0.25 mL syringe, Intravitreal, 0.07 mL Total Volume, Rx Only, Hospital/Office Use Only, Refrigerate, RC Outsourcing LLC, Lowellville, OH 44436.
Reason for Recall
Lack of assurance of sterility.
Recalling Firm
RC Outsourcing, LLC — Lowellville, OH
Classification
Class II — May cause temporary or medically reversible adverse health consequences.
Product Type
Drugs
Product Quantity
2,669 syringes
Distribution
Nationwide in the US
Code Information
Lot # 20250708-768A26, BUD: Oct 06, 2025 20250715-944DF2 BUD: Oct 13, 2025 20250722-55C603 BUD: Oct 20, 2025 20250722-5DC113 BUD: Oct 20, 2025
Status
Terminated
Voluntary / Mandated
Voluntary: Firm initiated